" class="no-js "lang="en-US"> ASCO Archives - Medtech Alert
Friday, August 01, 2025

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

The Combination of ISA101b and Libtayo® Shows Promising Results in Patients Whose Head and Neck Cancer Progressed on Anti-PD1 Therapy

ISA Pharmaceuticals B.V., a clinical-stage biotechnology company developing immunotherapies to treat cancers and serious infectious […]

Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel […]

Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting

Promontory Therapeutics, a clinical-stage pharmaceutical company advancing small molecule immunotherapies in oncology, announces preliminary data […]

Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline […]

Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion Study in GBM Patients

Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, has announced encouraging new data […]

Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more